Trial
NCT01051544
Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive
UnknownWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
Charta Foundation; Grifols Biologicals, LLC; CSL Behring; Biotest Pharmaceuticals Corporation; Grifols Therapeutics LLC
Condition
Severe Hemophilia A
Intervention
FVIII Concentrates
Why stopped
complete per PI
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-17